Eric Dessertenne

About Eric Dessertenne

Eric Dessertenne is an executive from the pharmaceutical and medical device sectors, best known for his long-running leadership role at BIOCORP Production. He joined the company in 2014 after building a career that combined corporate strategy, commercial development and life-science consulting. Available biographical information indicates that he holds a pharmacy degree from the University of Clermont-Ferrand, an MBA from ESSEC Business School, and is a graduate of ESSEC’s Therapeutic Innovation chair. Before joining BIOCORP, he began his career at Servier in the corporate strategy department, later moved to Servier’s Chinese subsidiary in Beijing, where he worked in marketing and sales-related functions, and then joined L.E.K. Consulting, where he advised clients in life sciences and private equity on growth opportunities, portfolio reviews and due diligence. At BIOCORP, Dessertenne first took on responsibilities as Head of Business Development & Commercial Operations, reflecting his focus on strategic growth and external development. He was later appointed Chief Operating Officer in 2016 and then Chief Executive Officer in December 2019. This internal progression shows a steady rise based on operational credibility and deep sector expertise. The company’s governance announcement at the time of his CEO appointment emphasized his central contribution to structuring the business, expanding French and international activities, and supporting BIOCORP’s strategic shift toward connected health. As BIOCORP’s leader, he helped drive the company’s positioning in innovative drug-delivery technologies, especially connected devices for injectable medicines. His period of leadership was associated with the acceleration of strategic partnerships with major international pharmaceutical groups, strengthening BIOCORP’s visibility in the connected health segment and supporting its broader industrial development. His profile stands out for combining pharmaceutical training, consulting experience and executive management skills. In practical terms, that mix enabled him to bridge innovation, operations and business development in a highly regulated medtech environment, while helping BIOCORP scale its technology platform and reinforce its market relevance.